

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q1 15-16	Q1 14-15	% Gr y-y
Home Markets	17,819	14,458	23.2%
India Formulations	7,416	6,749	9.9%
US Formulations	9,850	7,165	37.5%
Latin America Formulations	553	544	1.6%
Other Markets and Businesses	6,398	6,109	4.7%
Europe Formulations	836	1,012	-17.4%
Emerging Markets Formulations	1,255	1,050	19.5%
Consumer Wellness	1,107	1,075	2.9%
Animal Health & Others	763	776	-1.7%
APIs	980	1,007	-2.7%
JVs and Alliances	1,459	1,189	22.7%
Grand Total	24,217	20,568	17.7%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q1 15-16	Q1 14-15	% Gr y-y
Other Operating Income	1,224	297	311.5%
Dossier Fees			
Royalty Income	39	60	-34.8%
Net Gain on foreign currency transactions and translation (Refer Note below)	71	21	248.3%
Others	1,113	217	413.3%

Note : There was a net gain of Rs. 132 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q1 15-16. Thus, on aggregate level, there was a gain of Rs. 203 Mio. on operating transactions (above EBIDTA line) in Q1 15-16 vs gain of Rs. 48 Mio. in Q1 14-15. See details below for more clarity.

Rs. Mio.	Q1 15-16	Q1 14-15	% Gr y-y
Other Income	208	104	100.0%
Interest & Dividend income	134	84	58.5%
Profit on sale of investments	6	3	81.8%
Profit on sale of assets	0	0	-100.0%
Others	69	16	323.4%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q1 15-16	Q1 14-15	% Gr y-y
A. On operating transactions (above EBIDTA line)	-203	-48	-328.2%
a. Included in other income	-71	-21	-248.3%
c. Included in cost of goods	-132	-27	-388.9%
d. Included in other expenses			
B. On Foreign Currency Borrowings (part of interest cost)	22	-13	266.7%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-181	-61	-198.9%

Details of R&D Expenses

Rs. Mio.	Q1 15-16	Q1 14-15	% Gr y-y
Total R&D Expenses	1,684	1,057	59.3%

Consolidated Capex for Q1 FY16

**Rs. 1751
Mio.**

R&D capex included in above for Q1 FY16

**Rs. 35
Mio.**